Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 25 | 2025 | 637 | 8.140 |
Why?
|
| Liver Cirrhosis | 42 | 2025 | 832 | 6.670 |
Why?
|
| Hepatitis, Alcoholic | 6 | 2024 | 26 | 4.370 |
Why?
|
| Liver Transplantation | 21 | 2024 | 1037 | 3.510 |
Why?
|
| End Stage Liver Disease | 13 | 2024 | 181 | 3.310 |
Why?
|
| Acute-On-Chronic Liver Failure | 5 | 2023 | 64 | 2.560 |
Why?
|
| Hepatic Encephalopathy | 9 | 2024 | 76 | 2.370 |
Why?
|
| Hepatorenal Syndrome | 5 | 2024 | 28 | 2.290 |
Why?
|
| Severity of Illness Index | 17 | 2025 | 2914 | 1.460 |
Why?
|
| Hospitalization | 10 | 2025 | 1789 | 1.460 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2024 | 724 | 1.400 |
Why?
|
| Waiting Lists | 5 | 2024 | 228 | 1.260 |
Why?
|
| Vasoconstrictor Agents | 2 | 2024 | 136 | 1.040 |
Why?
|
| Hospital Mortality | 5 | 2024 | 1026 | 1.000 |
Why?
|
| Risk Factors | 19 | 2024 | 10319 | 0.920 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2024 | 55 | 0.880 |
Why?
|
| Arterial Pressure | 2 | 2024 | 112 | 0.870 |
Why?
|
| Prednisone | 1 | 2024 | 276 | 0.860 |
Why?
|
| Uromodulin | 2 | 2022 | 14 | 0.840 |
Why?
|
| Liver Failure, Acute | 2 | 2023 | 89 | 0.810 |
Why?
|
| Plasma Exchange | 1 | 2023 | 84 | 0.790 |
Why?
|
| Critical Illness | 3 | 2023 | 601 | 0.780 |
Why?
|
| Humans | 69 | 2025 | 125269 | 0.770 |
Why?
|
| Middle Aged | 31 | 2025 | 26943 | 0.760 |
Why?
|
| Ascites | 5 | 2025 | 88 | 0.740 |
Why?
|
| Alcoholism | 1 | 2023 | 231 | 0.730 |
Why?
|
| Prognosis | 10 | 2024 | 4646 | 0.710 |
Why?
|
| Factor V | 1 | 2020 | 18 | 0.670 |
Why?
|
| Retrospective Studies | 27 | 2024 | 16360 | 0.660 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2023 | 65 | 0.640 |
Why?
|
| Hypertension, Portal | 1 | 2020 | 78 | 0.640 |
Why?
|
| Patient Admission | 1 | 2020 | 185 | 0.610 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2023 | 227 | 0.590 |
Why?
|
| Adult | 31 | 2025 | 29652 | 0.560 |
Why?
|
| Kidney | 6 | 2024 | 1368 | 0.560 |
Why?
|
| Prospective Studies | 10 | 2025 | 6158 | 0.560 |
Why?
|
| Urea | 1 | 2018 | 231 | 0.550 |
Why?
|
| Decision Support Techniques | 2 | 2017 | 290 | 0.540 |
Why?
|
| Models, Statistical | 1 | 2019 | 471 | 0.530 |
Why?
|
| Male | 34 | 2025 | 61560 | 0.530 |
Why?
|
| Glomerular Filtration Rate | 3 | 2024 | 507 | 0.520 |
Why?
|
| Aged | 21 | 2025 | 19881 | 0.520 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 2 | 2024 | 19 | 0.510 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2017 | 95 | 0.510 |
Why?
|
| Health Surveys | 1 | 2017 | 244 | 0.500 |
Why?
|
| Multiple Organ Failure | 1 | 2017 | 141 | 0.500 |
Why?
|
| Female | 33 | 2025 | 66844 | 0.490 |
Why?
|
| Fatigue | 1 | 2016 | 190 | 0.470 |
Why?
|
| Communicable Diseases | 1 | 2017 | 161 | 0.470 |
Why?
|
| Liver Diseases | 3 | 2023 | 368 | 0.430 |
Why?
|
| Biomarkers | 5 | 2024 | 3091 | 0.430 |
Why?
|
| Adaptation, Psychological | 1 | 2016 | 448 | 0.410 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2025 | 398 | 0.370 |
Why?
|
| Survival Rate | 4 | 2024 | 2062 | 0.360 |
Why?
|
| Patient Readmission | 3 | 2024 | 385 | 0.350 |
Why?
|
| Intensive Care Units | 3 | 2023 | 493 | 0.330 |
Why?
|
| Early Diagnosis | 2 | 2024 | 183 | 0.330 |
Why?
|
| Acute Disease | 2 | 2023 | 1111 | 0.320 |
Why?
|
| Incidence | 4 | 2024 | 3148 | 0.320 |
Why?
|
| Prevalence | 2 | 2025 | 2459 | 0.250 |
Why?
|
| United States | 9 | 2024 | 10918 | 0.250 |
Why?
|
| Creatinine | 2 | 2024 | 391 | 0.250 |
Why?
|
| Disease Progression | 2 | 2023 | 2067 | 0.250 |
Why?
|
| Paracentesis | 1 | 2024 | 16 | 0.230 |
Why?
|
| Critical Pathways | 1 | 2025 | 79 | 0.230 |
Why?
|
| Fibrosis | 2 | 2023 | 436 | 0.230 |
Why?
|
| Polypharmacy | 1 | 2024 | 40 | 0.220 |
Why?
|
| Lypressin | 1 | 2024 | 16 | 0.220 |
Why?
|
| Cystatin C | 1 | 2024 | 58 | 0.220 |
Why?
|
| Cholinergic Antagonists | 1 | 2024 | 51 | 0.220 |
Why?
|
| Postoperative Hemorrhage | 2 | 2020 | 84 | 0.210 |
Why?
|
| Europe | 1 | 2024 | 355 | 0.210 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2023 | 930 | 0.200 |
Why?
|
| Insulins | 1 | 2023 | 17 | 0.200 |
Why?
|
| Risk Assessment | 3 | 2024 | 3465 | 0.200 |
Why?
|
| Delirium | 1 | 2022 | 55 | 0.190 |
Why?
|
| Vascular Calcification | 1 | 2023 | 57 | 0.190 |
Why?
|
| Reperfusion Injury | 1 | 2022 | 115 | 0.190 |
Why?
|
| Inpatients | 3 | 2022 | 500 | 0.190 |
Why?
|
| Medicaid | 2 | 2022 | 243 | 0.190 |
Why?
|
| Albumins | 1 | 2021 | 93 | 0.190 |
Why?
|
| Calcinosis | 1 | 2023 | 179 | 0.180 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2023 | 320 | 0.180 |
Why?
|
| Liver Neoplasms | 2 | 2023 | 1314 | 0.180 |
Why?
|
| Respiratory Insufficiency | 1 | 2023 | 226 | 0.180 |
Why?
|
| Hepatitis A | 1 | 2021 | 32 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2433 | 0.180 |
Why?
|
| Alcohol Drinking | 1 | 2023 | 346 | 0.180 |
Why?
|
| Drug Therapy, Combination | 1 | 2024 | 1172 | 0.180 |
Why?
|
| Syndrome | 1 | 2023 | 1121 | 0.170 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2021 | 108 | 0.170 |
Why?
|
| Quality of Life | 5 | 2023 | 1939 | 0.170 |
Why?
|
| Global Health | 1 | 2025 | 564 | 0.170 |
Why?
|
| Patient Selection | 1 | 2024 | 699 | 0.170 |
Why?
|
| Thrombelastography | 1 | 2020 | 57 | 0.160 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 160 | 0.160 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 162 | 0.160 |
Why?
|
| Blood Coagulation | 1 | 2020 | 125 | 0.160 |
Why?
|
| Health Literacy | 1 | 2020 | 80 | 0.160 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 238 | 0.160 |
Why?
|
| Insurance Coverage | 1 | 2020 | 122 | 0.160 |
Why?
|
| Treatment Outcome | 4 | 2024 | 12392 | 0.160 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2020 | 241 | 0.160 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 2894 | 0.160 |
Why?
|
| Bariatric Surgery | 1 | 2020 | 119 | 0.150 |
Why?
|
| Logistic Models | 2 | 2020 | 1812 | 0.150 |
Why?
|
| Primary Health Care | 1 | 2025 | 776 | 0.150 |
Why?
|
| Comorbidity | 2 | 2020 | 1535 | 0.150 |
Why?
|
| Hypotension | 1 | 2020 | 187 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2023 | 4818 | 0.150 |
Why?
|
| Proteomics | 1 | 2022 | 502 | 0.150 |
Why?
|
| Cardiomyopathies | 1 | 2023 | 499 | 0.150 |
Why?
|
| Hepatitis C | 1 | 2022 | 365 | 0.150 |
Why?
|
| Forecasting | 1 | 2019 | 351 | 0.140 |
Why?
|
| Palliative Care | 1 | 2022 | 434 | 0.140 |
Why?
|
| Executive Function | 1 | 2018 | 109 | 0.140 |
Why?
|
| Hepatitis C, Chronic | 1 | 2022 | 327 | 0.140 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 447 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 362 | 0.130 |
Why?
|
| Health Status Indicators | 1 | 2017 | 124 | 0.130 |
Why?
|
| Sepsis | 1 | 2020 | 482 | 0.130 |
Why?
|
| Coronary Artery Disease | 1 | 2023 | 814 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 434 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 647 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2019 | 1396 | 0.120 |
Why?
|
| Drug Therapy | 1 | 2015 | 87 | 0.120 |
Why?
|
| Lipid Accumulation Product | 1 | 2014 | 1 | 0.120 |
Why?
|
| Hepatitis B | 1 | 2016 | 160 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 874 | 0.110 |
Why?
|
| Mobile Applications | 1 | 2015 | 90 | 0.110 |
Why?
|
| Polytetrafluoroethylene | 1 | 2014 | 84 | 0.110 |
Why?
|
| Cognition | 1 | 2018 | 728 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2015 | 218 | 0.110 |
Why?
|
| Cytokines | 1 | 2019 | 1289 | 0.110 |
Why?
|
| Aminoglycosides | 1 | 2013 | 45 | 0.100 |
Why?
|
| Renal Replacement Therapy | 2 | 2024 | 142 | 0.100 |
Why?
|
| Fatty Liver | 1 | 2014 | 187 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1898 | 0.100 |
Why?
|
| Risk | 1 | 2014 | 756 | 0.100 |
Why?
|
| ROC Curve | 3 | 2022 | 571 | 0.100 |
Why?
|
| Liver | 2 | 2020 | 1748 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2015 | 399 | 0.090 |
Why?
|
| Stroke Volume | 2 | 2023 | 490 | 0.090 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2022 | 173 | 0.080 |
Why?
|
| Ventricular Function, Left | 2 | 2023 | 509 | 0.080 |
Why?
|
| Activities of Daily Living | 2 | 2022 | 407 | 0.080 |
Why?
|
| Obesity | 1 | 2020 | 2248 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2024 | 1360 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2020 | 3075 | 0.080 |
Why?
|
| Stents | 1 | 2014 | 888 | 0.070 |
Why?
|
| Adolescent | 3 | 2024 | 19362 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2024 | 2174 | 0.060 |
Why?
|
| Young Adult | 3 | 2024 | 9056 | 0.050 |
Why?
|
| Psychometrics | 2 | 2018 | 673 | 0.050 |
Why?
|
| Confusion | 1 | 2022 | 16 | 0.050 |
Why?
|
| Necrosis | 1 | 2023 | 208 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2024 | 126 | 0.050 |
Why?
|
| HIV Infections | 1 | 2014 | 1899 | 0.050 |
Why?
|
| Aftercare | 1 | 2023 | 149 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 2058 | 0.050 |
Why?
|
| Indiana | 1 | 2021 | 5 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 3432 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2025 | 543 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 126 | 0.050 |
Why?
|
| Karnofsky Performance Status | 1 | 2020 | 12 | 0.050 |
Why?
|
| Biliopancreatic Diversion | 1 | 2020 | 4 | 0.040 |
Why?
|
| Gastroplasty | 1 | 2020 | 11 | 0.040 |
Why?
|
| Acetaminophen | 1 | 2021 | 92 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 473 | 0.040 |
Why?
|
| Hospitals, Low-Volume | 1 | 2020 | 31 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2024 | 651 | 0.040 |
Why?
|
| Time Factors | 2 | 2024 | 6339 | 0.040 |
Why?
|
| Coronary Angiography | 1 | 2023 | 450 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2022 | 244 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 1117 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2022 | 278 | 0.040 |
Why?
|
| Gastrectomy | 1 | 2020 | 93 | 0.040 |
Why?
|
| Gastric Bypass | 1 | 2020 | 71 | 0.040 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2020 | 64 | 0.040 |
Why?
|
| Ischemia | 1 | 2022 | 363 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2023 | 496 | 0.040 |
Why?
|
| Sodium | 1 | 2020 | 298 | 0.040 |
Why?
|
| Swine | 1 | 2022 | 1210 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 320 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2022 | 872 | 0.040 |
Why?
|
| Poverty | 1 | 2022 | 425 | 0.040 |
Why?
|
| Length of Stay | 1 | 2024 | 1312 | 0.040 |
Why?
|
| Minority Groups | 1 | 2020 | 249 | 0.040 |
Why?
|
| Surgical Wound Infection | 1 | 2020 | 261 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2021 | 472 | 0.040 |
Why?
|
| Child | 3 | 2022 | 24431 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2020 | 1259 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2022 | 753 | 0.030 |
Why?
|
| Clinical Enzyme Tests | 1 | 2016 | 16 | 0.030 |
Why?
|
| Rats | 1 | 2022 | 3727 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2016 | 82 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2023 | 3304 | 0.030 |
Why?
|
| Platelet Count | 1 | 2016 | 136 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2016 | 157 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 316 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 919 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2016 | 327 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 6603 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 3738 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 1238 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5180 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2016 | 1565 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2014 | 941 | 0.020 |
Why?
|
| Animals | 1 | 2022 | 34238 | 0.010 |
Why?
|